Earnings | Focal One®

Skip to main navigation

Home
Technology
- Product Details
- HIFU Technology
Physicians
- Prostate Cancer Management
- Clinical Information
Patients
Company

Menu

Home
Technology
- Product Details
- HIFU Technology
Physicians
- Prostate Cancer Management
- Clinical Information
Patients
Company

FocalTherics™ - Investor Relations

Investor Relations

Overview
News & Events
- News
- Events & Presentations
Financial Information
Stock Information
Corporate Governance
Investor Resources
- Contact Us
- Email Alerts

code

Earnings

EDAP Reports Fourth Quarter 2020 Results and Provides Operational Update

Read more about EDAP Reports Fourth Quarter 2020 Results and Provides Operational Update

EDAP Announces Record Preliminary Unaudited Fourth Quarter 2020 Revenue of EUR 15.3 Million [$18.3 million], an Increase of 28% Year-Over-Year

Read more about EDAP Announces Record Preliminary Unaudited Fourth Quarter 2020 Revenue of EUR 15.3 Million [$18.3 million], an Increase of 28% Year-Over-Year

EDAP Announces Positive 24 Month Interim Results of French Urology Association (AFU) Sponsored Clinical Study comparing HIFU to Radical Prostate Surgery

Read more about EDAP Announces Positive 24 Month Interim Results of French Urology Association (AFU) Sponsored Clinical Study comparing HIFU to Radical Prostate Surgery

EDAP Reports Third Quarter 2020 Results and Provides Operational Update

Read more about EDAP Reports Third Quarter 2020 Results and Provides Operational Update

EDAP Reports Second Quarter 2020 Results and Provides Operational Update

Read more about EDAP Reports Second Quarter 2020 Results and Provides Operational Update

EDAP Reports First Quarter 2020 Results and Provides Operational Update

Read more about EDAP Reports First Quarter 2020 Results and Provides Operational Update

EDAP Reports Record Full Year 2019 Results and Provides Operational Update

Read more about EDAP Reports Record Full Year 2019 Results and Provides Operational Update

EDAP Reports 2019 Third Quarter and Nine Months Results

Read more about EDAP Reports 2019 Third Quarter and Nine Months Results

EDAP Reports 2019 Second Quarter Results

Read more about EDAP Reports 2019 Second Quarter Results

EDAP Reports 2019 First Quarter Results

Read more about EDAP Reports 2019 First Quarter Results

Pagination

Page 1
Next page

Subscribe to Earnings

Investor Contact

Louisa Smith

Gilmartin Group

investor.relations@focalone.com

EDAP TMS SA

investor.relations@focalone.com

Get Updates And Stay Connected

Get New Updates Directly To Your Inbox.

Email Address* Required

Focal One® - HIFU Prostate Tissue Ablation

Focal One^® has received regulatory clearance and is marketed in the United States, Europe, Canada, Korea, Russia, Brazil and other countries. In the United States, Focal One^® is indicated for the ablation of prostate tissue. Focal One^® is a registered trademark of EDAP TMS.

Discover More

FocalTherics Information

P: +1(512) 832-7956
E: investor.relations@focalone.com
A: 4410 El Camino Real, # 150,
Los Altos, CA 94022

EDAP TMS S.A., the issuer of record for the Company's publicly traded securities, is evolving its corporate brand to FocalTherics to better reflect its focused therapeutic ultrasound strategy and long-term growth vision. While the Company will continue to operate under its legal name, EDAP TMS S.A., it now does business as FocalTherics across its investor and corporate communications. This brand transition aligns the Company's identity with its expanding innovation portfolio while maintaining continuity, transparency, and regulatory compliance for shareholders. All historical filings, disclosures, and governance materials remain attributable to EDAP TMS S.A., ensuring clarity and consistency throughout this evolution.